Chapter 14 / Managing the Clinical Trial Lifecycle / Paid beta preview

Chapter 14: Treatment, Follow-Up, Monitoring, and Site Relationships

How treatment, follow-up, monitoring, safety, sites, and data must hold together during conduct. ## Enrollment Is Only The Beginning DIAB-220 had finally begun to feel alive. Participants were randomized [ICH E9]. Study drug was moving through pharmacy workflows. Sites were scheduling treatment visits, participants were completing electronic clinical outcome assessment (eCOA) diary entries, clinical research associates (CRAs) were writing monitoring visit reports, and the electronic data capture system (EDC) was filling with real trial data. Lauren Brooks felt relief for about a week. Then the conduct signals started arriving in pieces. One site had repeated delays dispensing study drug because pharmacy staff were unsure how the interactive response technology system (IRT) matched the pharmacy manual. Another site had two Week 12 HbA1c visits scheduled outside the allowed visit window. A third site was entering adverse events late. A fourth site had excellent enrollment but falling eCOA completion. The CRO's summary still said, "Overall conduct on track." Maggie Chen asked Lauren, "On track for what?" That question changed the chapter. The treatment period is the part of a trial when participants receive assigned study treatment or comparator. Follow-up is planned contact after treatment starts, pauses, ends, or after key visits, used to collect safety and outcome information. Monitoring is sponsor oversight of trial conduct, participant safety, protocol adherence, and data quality. It may be performed by sponsor staff or delegated to a clinical research organization (CRO), but delegated work still requires sponsor oversight. In Chapter 13, Lauren learned that enrollment is not success unless participants can stay engaged. Chapter 14 teaches the next lesson: after participants enter treatment and follow-up, the trial becomes an evidence-generating system in motion. Safety pathways, visit windows, source records, EDC entries, eCOA completion, drug accountability, protocol deviations, monitoring findings, and site relationships all begin to tell one story. The project manager's job is not to make medical judgments, monitor sites personally, or command investigators. The PM's job is to make the conduct picture visible, connect accountable owners, track actions, escalate risks, and keep the trial from mistaking activity for control. ## The FOLLOW Frame Maggie gave Lauren a new frame for active conduct: | Letter | Meaning | PM Question | |---|---|---| | F | Follow-Up Discipline | Are participants completing visits, labs, diaries, safety contacts, and endpoint windows? | | O | Oversight Signals | What are monitoring, data, safety, system, and site metrics telling us early? | | L | Local Site Relationships | Do sites trust the sponsor and CRO enough to surface problems quickly? | | L | Log and Learn | Are issues documented, trended, corrected, and fed back into operations? | | O | Operational Adherence | Are protocol, IRT, supply, consent, safety, and data workflows being followed? | | W | Watch The CTQs | Are the critical-to-quality [ICH E8(R1)] factors still protected during conduct? | Critical-to-quality [ICH E8(R1)] factors, or CTQs, are the features of a trial that matter most to participant protection and reliable results. In DIAB-220, CTQs included correct randomization, dosing according to assignment, key HbA1c endpoint visits, safety follow-up, eCOA completion, informed consent [FDA Informed Consent 2023] control, investigational product accountability, and retention after treatment discontinuation. FOLLOW helped Lauren stop treating monitoring reports, data listings, safety notifications, and site complaints as separate inboxes. They were different windows into the same trial. ## The Conduct Flow Rafael Ortiz drew the basic flow for Lauren because beginners often compress the whole middle of a trial into "patients are on study." | Stage | Plain Meaning | What Can Go Wrong | |---|---|---| | Randomized [ICH E9] or enrolled | Participant enters the protocol-defined study path | Wrong status, wrong arm, incomplete baseline readiness | | Treatment period | Participant receives assigned study treatment or comparator | Dosing error, IRT mismatch, drug accountability gap, missed safety check | | Scheduled visits | Protocol visits occur within required timing | Missed visit, out-of-window visit, incomplete labs, wrong assessment order | | Follow-up | Safety, endpoint, and status information continue to be collected | Participant burden, missed contact, unclear withdrawal status | | Treatment discontinuation | Participant stops assigned treatment | Follow-up may still be needed if protocol and consent allow | | Study discontinuation or withdrawal | Participant stops some or all study participation | Must respect voluntariness and document status accurately | | Completion | Participant completes required study participation | Data and records still need cleaning, reconciliation, and lock readiness | A visit window is the allowed timing range around a scheduled visit. A missed visit is a planned visit that does not occur. An out-of-window visit occurs outside the allowed range. These are not merely calendar nuisances. They can affect participant safety, endpoint timing, protocol adherence, and data interpretation. ## Who Owns What During Conduct Lauren's first instinct was to gather every issue into her tracker and drive each one herself. Maggie stopped her. "A good PM makes accountability clearer," Maggie said. "She does not become everyone's substitute." The team used the data-flow map to turn the details into operating choices the PM could assign, monitor,

...